2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aminotransferases (Transaminases)

Aminotransferases (Transaminases)

Aminotransferases (Transaminases)

Aminotransferases (transaminases) are enzymes that catalyze a transamination reaction between amino acids and α-keto acids. They mainly include glutamate-pyruvate transaminase (GPT), also known as alanine aminotransferase (ALT), and glutamate-oxaloacetate transaminase (GOT), also known as aspartate aminotransferase (AST). Aminotransferases (transaminases) play a crucial role in the biosynthesis of non-essential amino acids, helping cells generate the required amino acids by transferring amino groups. Aminotransferases (transaminases) are also involved in the nitrogen-containing compounds metabolism, converting amino acids into forms that are easily excreted or can be used in other metabolic pathways. ALT and AST are often used as clinical diagnostic indicators. An increase in their levels in the blood is often associated with liver diseases such as hepatitis and cirrhosis, heart diseases such as myocardial infarction, and muscle diseases such as polymyositis[1][2].

Aminotransferases (Transaminases) Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-158309
    hOAT-IN-1
    		Inhibitor
    hOAT-IN-1 (compound 5) is a mechanical inhibitor of human ornithine aminotransferase (hOAT). hOAT-IN-1 as a time-dependent inhibitor can form tightly bound PLP inhibitor adduct with hOAT. hOAT-IN-1 can result IN tight occupation of the active site of hOAT. hOAT-IN-1 can be used in the study of lung cell carcinoma .
    hOAT-IN-1
  • HY-171035
    PRL-295
    		Inhibitor
    PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction。PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen (HY-66005)-induced liver injury in mice.
    PRL-295
  • HY-169792
    HPG1860
    		Inhibitor
    HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC50 of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC50 values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH).
    HPG1860